Incannex Healthcare Inc.
IXHL Healthcare Drug Manufacturers Specialty & Generic
Incannex Healthcare Inc.’s revenue for fiscal 2025 (year ended June 2025) was $86,000.00, up 616.7% from fiscal 2024. In the quarter to June 2026, revenue fell 92.3%, EPS grew 99.0% and free cash flow grew 327.7%, each against the same quarter a year earlier.
Follow IXHL
Incannex Healthcare Inc. (IXHL) EV/Sales
As of 16 October 2026, Incannex Healthcare Inc. (IXHL) trades at a EV/Sales of −19.9×. Over the past ten years it has ranged from −25.0× (April 2026) to 636,556× (March 2022); the current reading is higher than 1% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.4× | — |
| FY2024 | 21.3× | (99.95%) |
| FY2023 | 45,484× | (37.88%) |
| FY2022 | 73,224× | (72.56%) |
| FY2021 | 266,811× | 0.00% |
| FY2020 | 266,811× | 0.00% |
| FY2018 | 266,811× | 0.00% |
| FY2017 | 266,811× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 25.0× | 33.21% |
| Sep 2024 | 18.8× | (99.99%) |
| Jun 2021 | 266,811× | 0.00% |
| Dec 2020 | 266,811× | 0.00% |
| 2 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. | −19.9× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| INCR InterCure Ltd. compare | 0.7× |
| SCYX SCYNEXIS, Inc. compare | 0.7× |
| CPHI China Pharma Holdings, Inc. compare | 8.1× |
| TXMD TherapeuticsMD, Inc. compare | 85.1× |
| TLPH Talphera, Inc. compare | 166× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)